AbbVie is forecast to report Q1 revenue of approximately $14.7bn, reflecting an 8% increase year-on-year. Strong sales of Skyrizi and Rinvoq are expected to offset declines following Humira's loss of exclusivity.

The company’s oncology investments hinge on significant clinical successes, but limited diversification beyond antibody-drug conjugates (ADCs) and select late-stage assets presents execution challenges.